The growth suppressor p53 is an important key element which controls cell cycle progression in response to cellular stress like DNA damage. Its ability to act as transcriptional activator or repressor links transcription and cell cycle control. Several target genes selectively transactivated by p53 are implicated in growth control, apoptosis and DNA repair. Here we report the interaction of p53 with another important dual player of cell cycle control and transcription, the protein kinase complex CDK7/cyclin H/Mat1 (CDK activating kinase, CAK kinase). This is implicated in the activating phosphorylation of CDK2/cyclin A kinase required to allow cells to proceed through the G 1 /S transition, and on the other hand, as a component of the basal transcription factor TFIIH found to be necessary for CTD phosphorylation of RNA polymerase II in order to allow elongation of transcription. Based on previous binding studies of p53 with other C-terminal interaction partners of p53 we demonstrate a direct physical interaction of p53 with cyclin H in vitro and in vivo. As a consequence of this interaction we tested the in¯uence of p53 on the kinase activity of CAK kinase for CTD and CDK2 phosphorylation. The addition of wild type p53 to the kinase reactions resulted in a signi®cant downregulation of CDK2 phosphorylation and CTD phosphorylation by the CDK activating kinase. On the other hand addition of a mutant p53His175 failed to downregulate CDK2 and CTD phosphorylation by the CDK activating kinase. In an attempt to support our ®ndings in vivo we measured CAK kinase activity in p21 7/7 and p53 7/7 mice embryonal ®broblasts under conditions when p53 gets activated by irradiation. In the case of p21 7/7 cells this led to a signi®cant reduction of CTD phosphorylation activity of the CDK activating kinase by irradiation of the cells. On the other hand in p53 7/7 cells no downregulation of CTD phosphorylation activity of CAK kinase was observed indicating that this kind of negative regulation of CAK kinase activity is exclusively due to a functional p53. These ®ndings imply a direct involvement of p53 in triggering growth arrest by its interaction with the CDK activating kinase complex without the need of cyclin-dependent kinase inhibitors (CKIs) and potentially suggest a new mechanism for p53-dependent apoptosis.
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Introduction
Transitions during the cell cycle are regulated by a family of cyclin-dependent kinases (CDKs) in order to let cells proceed through the cell cycle in a coordinated fashion. These kinase complexes, usually consisting of a catalytic (CDK) and a regulatory subunit (cyclin), underly tight regulations, in terms of phosphorylation/ dephosphorylation, subunit assembly or interaction with modulators of their activity like cyclin-dependent kinase inhibitory proteins (CKIs) (Pines, 1995) . One member of this family, the CDK7/cyclin H complex (CAK kinase), has recently drawn a lot of attention (Nigg, 1996) , since it could be demonstrated that the CDK7/cyclin H complex is not only involved in cell cycle progression by phosphorylating and hereby activating CDK2/cyclin A kinase to ensure the G 1 /S transition. Moreover, as a component of the general transcription factor TFIIH the CDK7/cyclin H kinase (Feaver et al., 1994; Roy et al., 1994) was found to be capable of phosphorylating the C-terminal heptad repeats of the large subunit of RNA polymerase II which appears to be necessary for the elongation step during transcription (Akoulitchev et al., 1995; MaÈ kela et al., 1995) . Puri®cation of the CDK7/cyclin H complex revealed that the kinase complex can be found in at least two distinct forms within the cell, either associated with the multi protein complex TFIIH or not, and in contrast to other cyclin-dependent kinases to copurify with a third factor, Mat1, which is believed to act as an assembly factor (Fisher et al., 1995) and to stabilize the kinase complex (Devault et al., 1995; Tassan et al., 1995) . Apparently association with TFIIH is considered to be critical for the substrate speci®city of the CDK7/cyclin H/Mat1 kinase complex (Yankulov and Bentley, 1997) . Association with TFIIH leads to a preference for the phosphorylation of the CTD of RNA polymerase II, whereas the free complex tends to show a higher speci®city for the activating phosphorylation of CDK2/ cyclin A kinase (Rossignol et al., 1997) .
Recently the tumour suppressor p53, a key regulator for cell growth and death (Levine, 1997) , was identi®ed as a new substrate for the CDK7/cyclin H/Mat1 kinase complex (Ko et al., 1997 , Lu et al., 1997 . As a transcription factor p53 responds to a variety of DNA damaging agents by transactivating the expression of proteins which control cellular growth resulting either in growth arrest or apoptosis. The best known example for a downstream regulator of growth is the p21 WAF1 gene product which selectively inhibits cyclin-dependent kinases (El-Deiry et al., 1993; Harper et al., 1994) . Activation of p21 WAF1 by p53 in response to DNA damage cause cells to arrest in G 1 (Pietenpol et al., 1994; Harper et al., 1994) to allow some time for the repair of damaged DNA or triggers programmed cell death when DNA repair fails (Attardi et al., 1996) . The transactivation of target genes like p21 WAF1 requires the activation of the sequence-speci®c DNA binding of p53 (Chin et al., 1997) which is thought to be mediated by a conformational transition of a latent to an activated state of p53 (Hupp and Lane, 1994) . p53 is the subject of various post-translational modi®cations like e.g. phosphorylation (Knippschild et al., 1996; Lohrum and Scheidtmann, 1996; Hecker et al., 1996) , glycosylation or acetylation (Meek, 1994) , and it could be demonstrated that phosphorylation by various kinases signi®cantly stimulated its ability for sequence speci®c DNA binding in vitro which is impaired in a wide variety of human tumours with mutated p53 (Steegenga et al., 1996) . Other interactions of the tumour suppressor p53 with components of TFIIH have been reported supporting the idea that p53 plays a direct role in DNA repair by its association with mismatched and damaged DNA (Lu et al., 1997) . At least three major components of TFIIH, XPB (ERCC2), XPD (ERCC3) and p62, are capable to interact with p53 in vitro and it has been demonstrated that wild type in contrast to mutant p53 potentially modulates TFIIH-associated nucleotide excision repair (NER) activity by inhibiting the intrinsic DNA helicase activity of XPD (ERCC3) and XPB (ERCC2) (Wang et al., 1995) . Apparently both helicase subunits of TFIIH exert additional functions during p53-induced apoptosis providing another functional link between p53 and TFIIH (Wang et al., 1996) .
Based on previous binding studies with other Cterminal binding partners of p53, in this report we demonstrate a direct physical interaction of p53 with cyclin H in vitro and in vivo. As a consequence of this interaction we tested the in¯uence of wild type p53 and mutant p53His175 on CDK2 phosphorylation as well as on CTD phosphorylation of the large subunit of RNA polymerase II by the trimeric CAK kinase complex. Wild type p53 proved to be an eective downregulator of the CAK kinase activity whereas mutant p53His175 had no eect on CAK kinase activity. On irradiation of p21 7/7 cells a signi®cant reduction of CAK kinase activity was observed, whereas cells lacking p53 showed no decrease in CAK kinase activity indicating that a functional p53 is required for a downregulation of CAK kinase in vivo. These ®ndings imply a direct involvement of p53 in triggering growth arrest by its interaction with the CAK kinase complex without the need of cyclin dependent kinase inhibitory proteins and potentially suggest a new mechanism for p53-dependent apoptosis.
Results
Cyclin H shares a common motif with the tms1 protein of ®ssion yeast responsible for the interaction with p53
Previously we reported the use of ®ssion yeast to clone potential interaction partners of p53. Strong overexpression of human p53 was found to be lethal leaving recipient yeast cells multiseptated and elongated. By exploiting the p53-induced lethality we cloned several multi copy suppressors from yeast and man (Wagner et al., 1991 (Wagner et al., , 1993 Bureik et al., 1997) . Among these suppressors we identi®ed the tms1 protein from ®ssion yeast and we were able to demonstrate a direct interaction of p53 with the tms1 protein in vivo and in vitro. To map more precisely the binding sites on both proteins we adapted an in vitro binding assay which had already proven useful for the mapping of the interaction of p53 with the b-subunit of protein kinase CK2 (Appel et al., 1995) and p34 cdc2 (Wagner et al., 1998) . By means of this method we were able to map precisely the p53 binding site on the tms1 protein comprising amino acids 116 ± 125 (YYITTEDFCT) (Appel et al., 1995) . Comparing the binding region of the tms1 protein with other protein sequences we noted similar amino acid patterns for the mcs2 protein from ®ssion yeast (HYSIEQFCT) (Molz and Beach, 1993 ) and its human homolog cyclin H (YYEKRLLEFCS) (MaÈ kela et al., 1994; Fisher and Morgan, 1994) . This is remarkable since a mcs2 deletion in ®ssion yeast results in the outgrowth of spores with a phenotype comparable to a strong overexpression of p53 in ®ssion yeast (data not shown). Based on these observations we tested the possibility of a direct interaction of p53 with cyclin H. In order to use cyclin H as a probe for binding assays on p53 a sequenced cyclin H cDNA was cloned into the bacterial expression vector pQE30 (Qiagen) to introduce a tag of six additional histidine residues at the N-terminus of expressed proteins. This allows a rapid single step puri®cation of recombinant cyclin H on a Ni 2+ -NTA agarose column. After successful expression and puri®cation of the cyclin H protein we tested its binding ability to dierent C-terminal fragments of human p53 comprising amino acids 264 ± 393, 289 ± 393, 315 ± 393 and 340 ± 393. For a FarWestern analysis total lysates of E. coli cells expressing the C-terminal fragments of p53 were subjected to SDS polyacrylamide gel electrophoresis. After renaturation the proteins were transferred to nitrocellulose ®lters and probed with cyclin H protein. The speci®c association of the cyclin H probe with dierent Cterminal p53 fragments was visualised by immunodetection with cyclin H speci®c antibodies ( Figure 1a ) which did not crossreact with the C-terminal fragments of p53 (data not shown). Figure 1a shows a typical Far-Western blot analysis where a speci®c binding of cyclin H protein to the C-terminal fragments of p53 between amino acids 264 ± 393, 289 ± 393, 315 ± 393 could be detected (lanes 1 ± 3). No such binding was observed in the case of the p53 fragment between amino acids 340 ± 393 (lane 4) although this protein was present on the ®lter (lane 8) which was controlled by immunodetection of an identically prepared ®lter with the p53 speci®c antibody PAb421 (lanes 5 ± 8). Nterminal fragments of p53 between amino acids 1 ± 289 showed no binding of cyclin H (data not shown). The results of these mapping studies indicate that cyclin H binds directly to p53 and that the interaction occurs between amino acids 315 ± 340 of p53 indicating that the binding is most likely mediated by a domain of cyclin H similar to the p53 binding site on the tms1 protein.
Since these binding assays rely on the correct renaturation of one binding partner after gel electrophoresis we performed an additional experiment to avoid potential problems arising from the renaturation step which we encountered in the case of full length p53 (data not shown). In this case we incubated puri®ed radioactive labelled cyclin H protein together with a bacterially produced C-terminal fragment of p53 (aa 264 ± 393), immunoprecipitated the C-terminal fragment afterwards by means of the p53-speci®c monoclonal antibody PAb421 (Harlow et al., 1981) and protein A sepharose (Pharmacia). After extensive washing the immunoprecipitates were analysed by SDS polyacrylamide gel electrophoresis and the dried gel was subjected to autoradiography. The cyclin H protein could be detected only in the presence of Cterminal fragments of p53 indicating that the cyclin Hp53 interaction is speci®c for the presence of the Cterminal fragments of p53 which were obviously refolding correctly during the renaturation step in our previous binding assays (data not shown).
In order to investigate whether the in vitro interaction of cyclin H with p53 can be reproduced in vivo we decided to transfect COS-1 cells transiently with a cyclin H expression vector to achieve an overexpression of cyclin H. Precleared lysates of the transfected COS-1 cells were subjected to immunoprecipitation by antibodies against CDK7, cyclin H and Mat1 (Santa Cruz). After precipitation the immunoprecipitates were washed several times before subjection to SDS polyacrylamide gel electrophoresis. After electrophoresis proteins were transferred onto nitrocellulose and subsequently probed with the p53-speci®c monoclonal antibody PAb421 to test the immunoprecipitates for the presence of p53. As shown in Figure 1b , this resulted in clearly detectable signals for p53 in case of the CDK7, cyclin H and Mat1 immuno-precipitates while no signals were detected in the corresponding control lanes loaded with the same amounts of antibodies as used for the immunoprecipitations indicating that small amounts of p53 are complexed with the CDK activating kinase in vivo.
Baculovirus based expression of a trimeric CAK kinase complex
To study the potential in¯uence of p53 on the CAK kinase complex all subunits were cloned into recombinant baculoviruses where CDK7 carried an additional N-terminal tag of six histidine residues for puri®cation purposes, cyclin H a GST-tag and Mat1 no tag at all. Coinfections of SF21 cells with recombinant baculoviruses of all subunits were cultured for 48 h, extracted and subjected to a native puri®cation on a Ni 2+ -NTA agarose column. Trimeric CDK7/cyclin H/Mat1 kinase complex was eluted from the column by increasing concentrations of imidazole. Best results were obtained with an imidazole concentration of about 100 mM yielding a virtually pure preparation of the trimeric kinase complex as judged by SDS polyacrylamide gel electrophoresis as shown in Figure 2a . In order to test our preparations of trimeric CDK7/cyclin H/Mat1 kinase complex for activity we used as a synthetic substrate a CTD peptide which mimicks four of 52 heptad repeats in the C-terminal domain (CTD) of the large subunit of RNA polymerase II. RNA polymerase II was shown to be eectively phosphorylated by the trimeric CDK7/cyclin H/Mat1 kinase complex within its C-terminal domain which is required at the transition of initiation to elongation during transcription (Akoulitchev et al., 1995) . Identical aliquots of the 5) , aa 289 ± 393 (lanes 2 and 6), aa 315 ± 393 (lanes 3 and 7) and aa 340 ± 393 (lanes 4 and 8) were separated on a 20% SDS polyacrylamide gel, renatured, transferred onto nitrocellulose membrane. The membrane (lanes 1 ± 4) was incubated with puri®ed cyclin H protein. After washing, the speci®c binding of cyclin H to the dierent p53 fragments was visualized by immunodetection with cyclin H speci®c antibodies and the ECL system (Amersham). The other half of the membrane was probed with the p53 speci®c antibody PAb421 in an immunodetection assay to ensure the presence of all p53 mutants on the ®lter (lanes 5 ± 8). (b) Coimmunoprecipitations of the CAK kinase subunits and p53 from COS-1 cells. COS-1 cells were transiently transfected with pCMVcyclin H. Seventy-two hours post transfection cleari®ed extracts of transfected cells were subjected to immunoprecipitations using polyclonal antibodies against cyclin H, CDK7 and Mat1(lanes 2 ± 4) and protein A sepharose. The washed immunoprecipitates were analysed on a 12.5% SDS polyacrylamide gel, transferred onto nitrocellulose and probed for the presence of p53 by using the p53-speci®c monoclonal antibody PAb421. Subsequently, the blot was developed using the ECL system (Amersham). To exclude any cross reactivities the same amount of antibodies as used for the immunoprecipitation described above were analysed on the same ®lter (lanes 5 ± 7). As a control protein A sepharose lacking any antibody was used (lane 1) for immunoprecipitation fractions from the Ni 2+ -NTA anity chromatography as shown in Figure 2a (lanes 1 ± 3) were incubated with the same amount of CTD substrate peptide and [ 32 P]g-ATP. After termination of the reactions by addition of SDS loading buer and boiling the samples were subjected to SDS polyacrylamide gel electrophoresis and autoradiography. As it is shown in Figure 2b this resulted in a readily detectable incorporation of radioactivity in added CTD substrate indicating that we have puri®ed an active trimeric CAK kinase complex.
p53 downregulates CAK kinase activity in vitro
Having demonstrated an interaction of p53 with the trimeric CDK7/cyclin H/Mat1 kinase complex in vitro and in vivo we reasoned whether p53 might in¯uence the kinase activity of the complex. To test this hypothesis we performed kinase reactions in the presence of wild type p53 and mutant p53His175 oering either puri®ed CDK2 or a synthetic CTD peptide as substrates. Wild type and mutant p53 as well as the GST-CDK2 K33R protein were expressed in bacteria and puri®ed either on a Ni 2+ -chelate agarose column in the case of p53 or on a GST-sepharose column in the case of GST-CDK2 K33R (Figure 2c ). The p53His175 mutant was chosen because it belongs to the so-called hot spot mutations of p53 which account for 22% of all mutations found in human tumours and fails to transactivate p53 responsive genes and to inhibit cell proliferation (Legros et al., 1994) . In order to measure the in¯uence of p53 on CDK2 phosphorylation puri®ed trimeric CAK kinase complex was preincubated with increasing amounts of either wild type p53 or mutant p53His175 protein for 30 min. at room temperature to allow complex formation. Afterwards we started the kinase reaction by addition of puri®ed GST-CDK2 K33R protein and radioactive [ 32 P]g-ATP. To avoid potential problems arising from the endogenous kinase activity of CDK2 we used the CDK2 K33R mutant which is de®cient for kinase activity. After incubation for 30 min at 378C the reactions were terminated and subjected to SDS polyacrylamide gel electrophoresis followed by autoradiography. As shown in Figure 3a addition of wild type p53 (16-fold molar excess over CAK kinase) resulted in a signi®cant decrease of incorporation of radioactivity in the oered CDK2 K33R protein whereas the addition of increasing amounts of p53His175 protein had no eect on CDK2 phosphorylation by the CAK kinase. Quanti®cation using a phosphoimager indicated a pronounced decrease of about 90% in the case of wild type p53 as judged from three independent experiments (Figure 3a, lane 3) . In the case of wild type p53 we observed only a poor phosphorylation of p53 protein during the kinase reactions, whereas the mutant p53His175 protein served as an ecient substrate for the CDK activating kinase (Figure 3a , lanes 5 and 6). This indicates that the observed decrease of the incorporation of radioactivity into the CDK2 K33R protein cannot be explained by a simple substrate competition since the amount of radioactive incorporation in wild type p53 is far to small to match the decrease of radioactive incorporation of the CDK2 substrate.
For the measurement of CTD phosphorylation activity the puri®ed trimeric CAK kinase complex was preincubated in the same way as described above either with wild type p53 or p53His175 mutant protein. Kinase reactions were started by addition of CTD peptide and [ 32 P]g-ATP and incubated for 30 min at 378C. After termination of the reaction by adding SDS loading buer and boiling the samples were subjected to SDS polyacrylamide gel electrophoresis followed by autoradiography. As shown in Figure 3b addition of wild type p53 resulted again in a pronounced decrease of radioactive incorporation in the CTD peptide whereas in the case of p53His175 the incorporation of radioactivity of the CTD peptide appeared to be unaected when compared to the control lacking any p53 protein. Quanti®cation of three independent experiments showed again a signi®cant decrease of about 90% in the case of wild type p53 for the incorporation of radioactivity in the CTD peptide (Figure 3b, lane 3) . We therefore conclude that wild type p53 in contrast to mutant p53His175 is an ecient negative regulator of CAK kinase activity at least in vitro.
Downregulation of CAK kinase activity in vivo depends on a functional p53
To support our in vitro ®ndings in vivo we reasoned that irradiation of cells-conditions under which p53 gets activated-should lead to a signi®cant downregulation of CAK kinase activity irrespective of the state of 3) were assayed for CTD phosphorylation activity. 5 mmoles of a synthetic CTD peptide comprising four times the heptad repeat of the large subunit of RNA polymerase II and 1 mCi[ 32 P]g-ATP (500 Ci/mmole) were added to the CAK kinase fractions, incubated for 30 min at 378C and analysed on a 20% SDS polyacrylamide gel followed by autoradiography. (c) Puri®ed wild type p53, p53His175 and GST-CDK2 K33R . Aliquots of puri®ed wild-type p53, p53His175 and GST-CDK2 K33R were analysed on a 12.5% SDS polyacrylamide gel and subsequently stained with Coomassie Brilliant Blue R-250 cells showed a signi®cant downregulation of CAK kinase activity in case of irradiation (lane 2) when compared to untreated cells ( lane 1). In contrast for p53 7/7 cells no change of CAK kinase activity was observed in response to irradiation indicating that the downregulation of CAK kinase activity observed in vivo is a p21-independent but p53-dependent process.
Discussion
Both factors, the tumour suppressor p53 as well as the CAK kinase complex, are implicated in the regulation of the cell cycle and transcription. Based on previous binding and mapping studies concerning other interaction partners of p53 (Wagner et al., 1991 (Wagner et al., , 1993 Bureik et al., 1997) , in the present report we demonstrate a direct interaction of p53 with the cyclin H subunit of the CAK kinase complex in vitro and in vivo. The binding data presented suggest that the interaction of p53 and cyclin H mainly occurs via the C-terminal domain of p53 between amino acids 315 ± 340 as it is the case for two other identi®ed binding partners of p53, the tms1 protein and the b-subunit of protein kinase CK2 (Wagner et al., 1993; Appel et al., 1995) .
Our study further shows that as a consequence of the interaction of p53 with the CAK kinase complex the kinase activity is modulated by wild type p53 in a negative fashion whereas the tumour mutant p53His175 failed to aect the kinase activity of trimeric CAK kinase. Moreover, we noted that phosphorylation of wild type p53 was poor, whereas the mutant p53His175 served as an ecient substrate for the CDK activating kinase. During our ongoing study two reports were published describing that p53 is a substrate for the CAK kinase complex (Ko et al., 1997; Lu et al., 1997) . Both papers report the phosphorylation of p53 by CDK7/cyclin H/Mat1 kinase, however, with dierent outcome concerning the potential phosphorylation site on p53. Whereas in one report the phosphorylation site of p53 was mapped to the C-terminus (Lu et al., 1997) , in the other report phosphorylation of p53 at Ser33 within the N-terminus was determined (Ko et al., 1997; Lu et al., 1997) . In the course of our studies we noticed that N-and Cterminal fragments of p53 were both phosphorylated by the CAK kinase complex (data not shown). Nevertheless, the observed downregulation of the CAK kinase activity with regard to both substrates, CDK2 and CTD, appeared to be independent of the phosphorylation of p53 by the CAK kinase. This 32 P]g-ATP (1 mCi), followed by incubation for 30 min at 378C. Subsequently the reactions were terminated and analysed on a 20% SDS polyacrylamide gel followed by autoradiography. For quanti®cation the corresponding signals obtained from three independent experiments were quanti®ed using a phosphoimager. The mean values and standard deviations are shown in per cent of the incorporation of radioactivity in the substrate when no p53 protein was present Regulation of CAK kinase by p53 E Schneider et al downregulation of the CAK kinase by p53 cannot be explained by a simple substrate competition since the observed amounts of radioactive incorporation in wild type p53 were far too small to account for the observed decrease of the radioactive incorporation of CDK2/ CTD substrate in comparison to a control reaction. On the other hand the mutant p53His175 protein served as an ecient substrate for the CAK kinase and no substantial decrease of incorporation of radioactivity in CDK2 and CTD substrate was observed. These in vitro data are further supported by the fact that under conditions when p53 gets activated, e.g. by irradiation, a downregulation of CAK kinase activity is only observed in the presence of a functional p53 while a functional p21 is apparently not required.
What are the implications of our ®ndings in the light of the current knowledge how growth arrest is achieved by p53? Normal cells respond to genotoxic stress by activating p53 which in turn transactivates several genes involved in growth control, apoptosis and/or DNA repair. Most important in terms of growth arrest is the p21 WAF1 gene product which is a potent inhibitor for cyclin-dependent kinases. It is thought to be responsible for a G 1 arrest by inhibiting CDK2/cyclin A kinase whose enzymatic activity is essential for the G 1 /S transition during cell cycle. However, there is evidence that p21 WAF1 might be only in part responsible for growth arrest. It has been reported that the stable expression of wild type c-abl can induce the expression of p21 WAF1 followed by a downregulation of CDK2 kinase activity when the cells were exposed to ionizing radiation. However, p21 WAF1 appears to be dispensable since the same experiment in p21 WAF1 -de®cient cells resulted in a downregulation of CDK2 kinase activity as well. Moreover, in an experiment using p53-de®cient cells no such eect was observed indicating that growth arrest follows a p53-dependent p21 WAF1 -independent regulation (Yuan et al., 1996) . This is in good agreement with our data which suggest that in addition to the transactivation of p21 WAF1 p53 can act as a potent regulator of the CAK kinase complex. In response to DNA damage wild type p53 in contrast to mutant p53 could downregulate CAK kinase activity, and therefore preventing an activating T-loop phosphorylation of CDK2 which in turn would result in a G 1 arrest of the cells. This implies that even in the absence of p21 WAF1 p53 would be capable of mediating a G 1 arrest. Downregulation of CAK kinase activity by p53 might have additional consequences since other cyclin-dependent kinases like cdc2 also require the Tloop phosphorylation for activation and therefore could account for a p53-mediated cell cycle arrest in G 2 (Guillouf et al., 1995; Han et al., 1995) .
What are the implications of our ®ndings in the light of the current knowledge how p53 triggers apoptosis? As a component of the general transcription factor TFIIH the CAK kinase (Feaver et al., 1994; Roy et al., 1994) was found to be capable of phosphorylating the C-terminal heptad repeats of the large subunit of RNA polymerase II which appears to be necessary for the transition of initiation to elongation of transcription (Akoulitchev et al., 1995; MaÈ kela et al., 1995) . Recent ®ndings that transformed cells require a continous activity of RNA polymerase II to resist an oncogene-induced apoptosis (Ljungman and Zhang, 1996) led to a model for the induction of apoptosis (Koumenis and Giaccia, 1997) . According to the model a balance of activators and inhibitors of apoptosis exists within a cell. This implies that the state of such an equilibrium is strictly dependent on a continous gene expression and an inhibition or downregulation of RNA polymerase II activity would result in a balance shift of the activator/inhibitor ratio favouring the more stable activators of apoptosis. All potential regulators of the RNA polymerase II activity would therefore in¯uence programmed cell death directly. This hypothesis is in good agreement with the observed downregulation of CAK kinase activity by p53 since the kinase activity was shown to be required for the transition of initiation to elongation during transcription. By downregulating the TFIIH associated CAK kinase activity p53 could directly trigger apoptosis by blocking transcription. This is further supported by data which show that exposure to ionizing radiation results in activation of p53 and in inhibition of total RNA and mRNA synthesis (Ljungman and Zhang, 1996) . Moreover, it has been demonstrated that the CAK kinase activity which was found to be constant during the cell cycle, is signi®cantly reduced after UV light irradiation (Adamczewski et al., 1996) . In summary our data suggest novel pathways how p53 can achieve a growth 7/7 MEF cells and p53 7/7 MEF cells were treated with 0 or 40 J/m 2 UV (254 nm) and cultivated with fresh medium for 16 h, harvested and extracted. CAK kinase of these cells was immunoprecipitated using polyclonal antibodies against cyclin H and tested for their CTD phosphorylation activity. The activity of the washed immunoprecipitates was measured by coincubation with [ 32 P]g-ATP and CTD peptide. After separation of the reaction mixture on a SDS polyacrylamide gel, incorporation of radioactivity on the CTD peptide was quanti®ed using a phosphoimager. The mean values and standard deviations of ®ve independent experiments are shown in per cent of the incorporation of radioactivity into the substrate when the CAK kinase was precipitated from non-irradiated cells arrest irrespective of the state of inhibitors for cyclindependent kinases or can induce apoptosis within cells in a response to irradiation activated p53.
Materials and methods

Plasmids and recombinant baculoviruses
Corresponding cDNAs of cyclin H, CDK7 and Mat1 were isolated by PCR from HeLa and human testis cDNA libraries in lgt11 (Clontech) and veri®ed by sequencing using an ALF express (Pharmacia, Freiburg, Germany). The cyclin H cDNA was cloned into the bacterial expression vector pQE30 (Qiagen) carrying an additional N-terminal tag of six histidine residues. For the bacterial expression of wild type p53 and mutant p53His175 in pET19b (Novagen) and C-terminal fragments of p53 (aa 264 ± 393, aa 289 ± 393, aa 315 ± 393, aa 340 ± 393) in pQE30 (Qiagen, Heidelberg, Germany) previously described constructs were used (Appel et al., 1995; Wagner et al., 1998) . For GST-CDK2 K33R expression a pGEX4-GST-CDK2 K33R vector (kindly provided by D Hermand and T MaÈ kela) was used. For baculovirus expression the CDK7 cDNA was cloned into the pBacPAK vector (Clontech), the cyclin H cDNA into pAcG-2T vector (Pharmingen, San Diego, USA) and the Mat1 cDNA into the pVL1392 vector (Pharmingen), respectively. To produce recombinant baculoviruses the transfervectors were recombinated with Baculo Gold DNA, using the Baculo Gold system (Pharmingen, San Diego, USA) according to the manufacturer's recommendations.
Expression and puri®cation of bacterially produced proteins
Preparation of bacterial extracts containing C-terminal fragments of p53 Transformed E. coli cells (M15 transformed with C-terminal fragments of p53 in the pQE vector) were grown to early log phase and induced for 2 h with 1 mM isopropyl-b-D-thiogalactopyranosid (IPTG) at 378C. Cells from 10 ml bacterial cultures were resuspended in 1 ml SDS loading buer (130 mM Tris/HCl, pH 6.8, 0.02% (w/v) bromphenolblau, 10 mM 2-mercaptoethanol, 20% (v/v) glycerin, 4% (w/v) SDS), soni®cated and centrifuged. Expression and puri®cation of cyclin H, wild type p53 and mutant p53His175 Transformed E. coli cells (M15 transformed with pQE-cyclin H, BL21 transformed with pET19b-p53wt or pET19b-p53His175) were grown to early log phase and induced for 6 h with 1 mM IPTG at 308C. Cells from 1 l bacterial cultures were resuspended in 6 M guanidine hydrochloride, 0.1 sodium phosphate, pH 8.0 and lysed overnight on ice. After precipitating cellular debris, the cleari®ed supernatants were applied onto a Ni 2+ -chelate agarose (Qiagen). The chelate resins were washed with 10 volumes each of lysing buer, pH 6.0, containing 20 mM imidazole. After washing the resins with lysing buer, pH 8.0, containing 20 mM imidazole proteins were eluted with lysing buer, pH 8.0, containing 300 mM imidazole and dialyzed against 20 mM Tris/HCl, pH 8.0, 100 mM KCl, 5 mM MgCl 2 , 0.1% Tween 20 and stored on ice before use.
Expression and puri®cation of GST-CDK2 K33R For the puri®cation of the GST-CDK2 K33R protein transformed E. coli (BL21) cells were induced as described above. For lysis harvested cells were resuspended in extraction buer (100 mM Tris/HCl, pH 8.0, 100 mM NaCl, 0.1% Tween-20) with addition of 1 mg/ml lysozyme and incubated for 15 min on ice. After soni®cation cleari®ed supernatant was loaded onto GSH-sepharose (Pharmacia, Freiburg, Germany). After extensive washing of the resin with extraction buer the CDK2 K33R protein was eluted with extraction buer containing 20 mM glutathione and stored on ice before use.
Far-Western blot analysis
Total lysates of E. coli (M15) cells expressing C-terminal fragments of p53 (aa 264 ± 393, aa 289 ± 393, aa 315 ± 393, aa 340 ± 393) were subjected to SDS polyacrylamide gel electrophoresis without boiling prior to loading the gel. After renaturation in 106 concentrated PBS at 48C for 1 h, proteins were transferred onto nitrocellulose ®lter. The ®lter was blocked for 1 h at 48C with 5% (w/v) dry milk in binding buer (20 mM Tris/HCl, pH 8.0, 100 mM KCl, 5 mM MgCl 2 , 0.1% Tween 20). One half of the ®lter was probed with 2 mg puri®ed cyclin H protein in binding buer for 1 h at 48C under gentle agitation. After washing twice, bound cyclin H was visualised by immunodetection with cyclin H speci®c antibodies. The other half of the ®lter ± identical loaded as the ®rst one ± was used in an immunodetection assay with the p53 speci®c antibody PAb421 to control the presence of all C-terminal deletion mutants on the nitrocellulose ®lter.
Cell culture, transfection and immunoprecipitation COS-1 cells were maintained in DMEM supplemented with 10% fetal calf serum. For transient transfections 3 ± 9610 5 cells were seeded into 10 cm petri dishes and transfected the following day by DEAE dextrane standard procedure. Cells were transfected with 10 mg of pCMV-cyclin H vector, harvested 48 ± 72 h post transfection, washed with PBS and extracted in 100 mM Tris/HCl, pH 9.0, 120 mM NaCl, 0.5% NP40 containing complete protease inhibitor cocktail (complete TM , Boehringer Mannheim, Germany). Cleari®ed supernatants were subjected to immunoprecipitation using polyclonal rabbit antibodies against cyclin H (C-18), CDK7 (FL-346) and Mat1 (FL-309, Santa Cruz) and protein A sepharose (Pharmacia) for 16 h at 48C. After washing with extraction buer immunoprecipitates were analysed on a 12.5% SDS polyacrylamide gel, transferred onto nitrocellulose, probed for the presence of p53 with the monoclonal antibody PAb421 and developed using the ECL system (Amersham, Braunschweig, Germany) according to the manufacturer's recommendations.
UV treatment of p21
7/7 or p53 7/7 MEF cells and measurement of CAK kinase activity p21 7/7 (kindly provided by P Leder, Boston, USA) and p53 7/7 mouse embryonal ®broblasts (MEF) (kindly provided by G Brandner, Freiburg, Germany) cells were maintained in Dulbecco's modi®ed Eagles medium (DMEM) with 10% fetal calf serum. Subcon¯uent p21 7/7 or p53 7/7 MEF cells (each 0.5610 7 cells) were radiated with 40 J/m 2 UV at 254 nm and cultivated for 16 h with fresh medium. Unradiated control cells were also grown with fresh medium for 16 h. Cells were washed twice in PBS, harvested and soni®cated in lysis buer (20 mM Tris/ HCl, pH 8.0, 100 mM KCl, 10 mM MgCl 2 , 0.1% (v/v) Tween-20) containing a protease inhibitor cocktail (complete TM , Boehringer Mannheim). Cleari®ed extracts (800 mg total protein for an immunoprecipitation) were subjected to immunoprecipitation using polyclonal antibodies against cyclin H (FL-324, Santa Cruz) and a mixture of protein A-and protein G-sepharose (Pharmacia) for 1 h at 48C. After extensively washing with lysis buer the immunoprecipitates were analysed for CTD phosphorylation activity as described above except for the reaction buer which was identical to the lysis buer. Incorporation of radioactivity into the CTD peptide was quanti®ed using a phosphorimager. The mean values and standard deviations of ®ve independent experiments (precipitation and activity measurement) were calculated and the results of the irradiated cells were expressed in relation to the results of the corresponding unradiated cells.
Baculovirus expression and puri®cation of CAK kinase
Sf21 insect cells were triple infected with recombinant baculoviruses expressing CDK7 (m.o.i. 2), cyclin H and Mat1 (m.o.i. 10). After 48 h cells were lysed in a hypotonic buer containing 20 mM NaH 2 PO 4 , pH 7.4, 20 mM NaCl, 0.5 mM DTT with protease inhibitors (complete TM , Boehringer Mannheim) on ice for 15 min., soni®ed and cleari®ed by centrifugation. The supernatant was loaded onto a Ni 2+ -chelate agarose (Qiagen) and washed with 20 mM Tris/HCl, pH 7.8, 300 mM KCl, 5 mM MgCl 2 , 0.1% Tween 20. Elution of trimeric CAK kinase complex was achieved by elution with washing buer containing 100 mM imidazole and stored on ice before use.
CDK2 phosphorylation assay
Kinase reactions were performed in 30 mM Tris/HCl, pH 7.8, 90 mM KCl, 12 mM MgCl 2 , 40 mM HEPES, 2.5 mM glutathione, 3 mM imidazole using 1 pmole puri®ed trimeric CAK kinase throughout. Various amounts of puri®ed p53 protein (0, 200 and 1000 ng) were added and incubated for 30 min at room temperature to allow complex formation. To start the kinase reaction 3 mg puri®ed GST-CDK2 K33R protein and [
32 P]g-ATP (1 mCi; 500 Ci/mmole) were added and incubated for 30 min at 378C. Finally, 56 conc. SDS loading buer (130 mM Tris/HCl, pH 6.8, 0.02% (w/v) bromphenolblue, 10 mM 2-mercaptoethanol, 20% (v/v) glycerin, 4% (w/v) SDS) was added, boiled for 3 min and samples were analysed on a 12.5% SDS polyacrylamide gel followed by autoradiography. Signals were quanti®ed using a phosphoimager.
CTD phosphorylation assay
As a substrate served 5 mmoles of a synthetic peptide comprising four times the hepta repeats (YSPTSPS) of the C-terminal domain (CTD) of the large subunit of human RNA polymerase II synthesized on an ABI peptide synthesizer (kindly provided by Dr W Nastainczyk, Medical Biochemistry and Molecular Biology, University of the Saarland). Assays were performed as described above except for the reaction buer which contained 20 mM Tris/HCl, pH 7.8, 110 mM KCl, 10 m MgCl 2 , 0.1% Tween 20 and 3 mM imidazole and separation of the samples on a 20% SDS polyacrylamide gel.
